Nicolas Stocker

Dr. Nicolas Stocker

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
PDF file
LRLaure Ricard
Laure Ricard
VJVincent Jachiet
Vincent Jachiet
FMFlorent Malard
Florent Malard
YYYishan Ye
Yishan Ye
NSNicolas Stocker
Nicolas Stocker
AMArsene Mekinian
Arsene Mekinian
Objectives Systemic sclerosis (SSc) is an autoimmune disease characterised by widespread fibrosis, microangiopathy and autoantibodies. Follicular helper T (Tfh) cells CD4+CXCR5+PD-1+ cooperate with B lymphocytes to induce the differentiation of plasmocytes secreting immunoglobulins (Ig). Circulating Tfh (cTfh) cells are increased in several autoimmune diseases. However, there are no data about cTfh cells and their interaction with B cells in SSc. The aim of this study was to perform a quantitative and functional analysis of cTfh cells in SSc. Methods Using flow cytometry, we analysed cTfh cells from 50 patients with SSc and 32 healthy controls (HC). In vitro coculture experiments of sorted cTfh and B cells were performed for functional analysis. IgG and IgM production were measured by ELISA. Results We observed that cTfh cell numbers are increased in patients with SSc compared with HC. Furthermore, the increase in cTfh cells was more potent in patients with severe forms of SSc such as diffuse SSc and in the presence of arterial pulmonary hypertension. cTfh cells from patients with SSc present an activated Tfh phenotype, with high expression of BCL-6, increased capacity to produce IL-21 in comparison with healthy controls. In vitro, cTfh cells from patients with SSc had higher capacity to stimulate the differentiation of CD19+CD27+CD38hi B cells and their secretion of IgG and IgM through the IL-21 pathway than Tfh cells from healthy controls. Blocking IL-21R or using the JAK1/2 inhibitor ruxolitinib reduced the Tfh cells’ capacity to stimulate the plasmablasts and decreased the Ig production. Conclusions Circulating Tfh cells are increased in SSc and correlate with SSc severity. The IL-21 pathway or JAK1/2 blockade by ruxolitinib could be a promising strategy in the treatment of SSc.

25 January 2024 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
IDIman Abou Dalle
Iman Abou Dalle
RDRemy Dulery
Remy Dulery
NMNour Moukalled
Nour Moukalled
LRLaure Ricard
Laure Ricard
NSNicolas Stocker
Nicolas Stocker
Ali BazarbachiAli Bazarbachi
Ali Bazarbachi
Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing the treatment landscape of B-cell non-Hodgkin’s lymphoma (B-NHL). In the relapsed/refractory setting, salvage chemotherapy and autologous stem cell transplantation are capable of curing 50% of patients, whereas the other half will have a dismal outcome with a median overall survival of less than 12 months. This unmet need reinforced the importance of innovative therapies like the BsAbs and CAR-T cell therapies. In this review, we delve into BsAbs in B-NHL from the preclinical development to clinical data in both refractory and frontline settings, and then discuss future perspectives.

27 September 2019 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
NSNicolas Stocker
Nicolas Stocker
MLMyriam Labopin
Myriam Labopin
IBInès Boussen
Inès Boussen
OPOlivier Paccoud
Olivier Paccoud
ABAgnès Bonnin
Agnès Bonnin
EBEolia Brissot
Eolia Brissot

1 January 2020 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
NSNicolas Stocker
Nicolas Stocker
BGBéatrice Gaugler
Béatrice Gaugler
MLMyriam Labopin
Myriam Labopin
AFAgathe Farge
Agathe Farge
YYYishan Ye
Yishan Ye
FMFlorent Malard
Florent Malard
Objectives: Haploidentical haematopoietic cell transplantation (Haplo‐HCT) using peripheral blood stem cell (PBSC) grafts and post‐transplant cyclophosphamide (PTCy) is being increasingly used; however, data on immunological reconstitution (IR) are still scarce.Methods: This retrospective study evaluated T‐cell immunological reconstitution in 106 adult patients who underwent allogeneic haematopoietic cell transplantation for haematologic malignancies between 2013 and 2016.Results: At D30, while conventional T cells reached similar median counts in Haplo‐HCT recipients (n = 19) and controls (n = 87), γδ and Vδ2+ T‐cell median counts were significantly lower in Haplo‐HCT recipients and it persists at least until D360 for Vδ2+ T cells. PTCy induces a significant reduction in early γδ and Vδ2+ T‐cell proliferation at D 7. At one year, the rate of increase in Epstein–Barr virus (EBV) viral load was significantly higher in Haplo‐HCT recipients as compared to controls (61% versus 34%, P = 0.02). In multivariate analysis, a higher γδ T‐cell count (> 4.63 μL−1) at D30 was the only independent parameter significantly associated with a reduced risk of increase in EBV viral load (RR 0.34; 95% CI, 0.15–0.76, P = 0.009).Conclusion: Immunological reconstitution of γδ T cells is significantly delayed after Haplo‐HCT using PTCy and low‐dose ATG and is associated with an increased risk of increase in EBV viral load.

8 April 2019 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
NSNicolas Stocker
Nicolas Stocker
RDRemy Duléry
Remy Duléry
GBGiorgia Battipaglia
Giorgia Battipaglia
EBEolia Brissot
Eolia Brissot
CMClémence Médiavilla
Clémence Médiavilla
FMFlorent Malard
Florent Malard

28 January 2020 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
NSNicolas Stocker
Nicolas Stocker
BGBéatrice Gaugler
Béatrice Gaugler
LRLaure Ricard
Laure Ricard
FVFrédéric de Vassoigne
Frédéric de Vassoigne
ZMZora Marjanovic
Zora Marjanovic
FMFlorent Malard
Florent Malard
Background: Daratumumab (Dara), an anti‐CD38 monoclonal antibody, has an immunologic mechanism of action through targeting of CD38 expressing immune cells in patients with multiple myeloma (MM). Furthermore, it was recently shown that CD38 upregulation in tumors, is a major mechanism of acquired resistance to antiprogrammed cell death 1 (PD‐1)/programmed cell death ligand 1 (PD‐L1). Therefore, we decided to evaluate the immunomodulatory effects of CD38 blockade by Dara on the PD‐L1 expressing immune cells.Methods: We analyzed CD38 and PD‐L1 expression on immune cells at different time points in 18 newly diagnosed MM receiving bortezomib, lenalidomide and dexamethasone, with or without Dara.Results: We first confirmed that CD38 is widely expressed on immune cells, with the strongest expression on plasmacytoid dendritic cells (pDC). Furthermore, Dara induces a strong depletion of pDC in addition to the well‐known rapid depletion of natural killer cells. Finally, we found that PD‐L1 expression on antigen‐presenting cells (APC) increases with MM treatment in patients that did not received Dara, while addition of Dara prevents this increase.Conclusion: Overall, our results suggest new mechanisms of action of Dara through depletion of pDC and prevention of PD‐L1 upregulation expression on APC. Our finding provides new evidences for development of therapeutic strategies targeting both CD38 and PD‐L1/PD‐1 pathway in patients with MM.